Hepcvel, also known as “EPCLUSA®, Velpanat, Sofosvel, MyHep All, Velasof” is a fixed dose combination medication for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5, or 6 infections without cirrhosis or with compensated cirrhosis and in combination with ribavirin for those with decompensated cirrhosis. Hepcvel combines Sofosbuvir 400mg and velpatasvir 100mg. It is more than 90% effective for hepatitis C. Sofosbuvir 400mg/Velpatasvir 100 mg’s brand name is EPCLUSA® by Gilead. Hepcvel is a generic oncologic prescription medicine from Cipla, which is one of the biggest pharmaceutical company in India.
